[Site-specific monoPEGylated interferon alpha2a mediated by microbial transglutaminase]

Area of Science:

• Biotechnology
• Protein Engineering
• Pharmacology

Background:

• PEGylation enhances protein drug properties like half-life and reduces immunogenicity.
• Non-specific PEGylation methods yield heterogeneous mixtures, complicating therapeutic development and regulatory approval.
• Enzymatic PEGylation offers a site-specific approach to overcome these limitations.

Purpose of the Study:

• To develop a site-specific PEGylation method for human interferon alpha 2a (IFN α2a) using microbial transglutaminase (mTGase).
• To evaluate the impact of site-specific PEGylation on IFN α2a's structure, bioactivity, and pharmacokinetic profile.

Main Methods:

• Computational analysis predicted Gln101 as a potential PEGylation site on IFN α2a.
• IFN α2a was PEGylated using Y-shaped PEG40k-NH2 mediated by mTGase.
• Circular dichroism (CD) assessed secondary structure preservation.
• Bioactivity and pharmacokinetic studies were conducted in rats.

Main Results:

• mTGase mediated site-specific PEGylation of IFN α2a exclusively at Gln101, producing a single mono-conjugate (PEG-Gln101-IFN α2a).
• CD studies confirmed that PEG-Gln101-IFN α2a retained the secondary structure of native IFN α2a.
• PEG-Gln101-IFN α2a demonstrated significantly improved bioactivity and pharmacokinetic profiles compared to unmodified IFN α2a and PEGASYS.

Conclusions:

• Site-specific PEGylation of IFN α2a at Gln101 via mTGase is feasible and yields a homogeneous product.
• This enzymatic approach preserves protein structure and enhances therapeutic efficacy.
• Enzymatic PEGylation represents a promising strategy for developing improved protein-based therapeutics.